Astrocytic TDP-43 pathology in Alexander disease by Walker, Adam K. et al.
Neurobiology of Disease
Astrocytic TDP-43 Pathology in Alexander Disease
AdamK.Walker,1* Christine M. LaPash Daniels,3* James E. Goldman,5 John Q. Trojanowski,1,2 Virginia M.-Y. Lee,1,2
and Albee Messing3,4
1Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine and 2Institute on Aging, Perelman School of Medicine,
University of Pennsylvania, Philadelphia, Pennsylvania 19104, 3Waisman Center and 4Department of Comparative Biosciences, University of Wisconsin-
Madison, Madison, Wisconsin 53705, and 5Department of Pathology and Cell Biology, Columbia University, New York, New York 10032
Alexander disease (AxD) is a rare neurodegenerative disorder characterized pathologically by the presence of eosinophilic inclusions
known as Rosenthal fibers (RFs) within astrocytes, and is caused by dominant mutations in the coding region of the gene encoding glial
fibrillary acidic protein (GFAP). GFAP is the major astrocytic intermediate filament, and in AxD patient brain tissue GFAP is a major
component of RFs. TAR DNA binding protein of 43 kDa (TDP-43) is the major pathological protein in almost all cases of the neurode-
generative disease amyotrophic lateral sclerosis (ALS) and50% of frontotemporal lobar degeneration (FTLD), designated as FTLD-
TDP. In ALS and FTLD-TDP, TDP-43 becomes insoluble, ubiquitinated, and pathologically phosphorylated and accumulates in
cytoplasmic inclusions in both neurons and glia of affected brain and spinal cord regions. Previously, TDP-43 was detected in RFs of
human pilocytic astrocytomas; however, involvement of TDP-43 in AxD has not been determined. Here we show that TDP-43 is present
in RFs in AxD patient brains, and that insoluble phosphorylated full-length and high molecular weight TDP-43 accumulates in white
matter of such brains. Phosphorylated TDP-43 also accumulates in the detergent-insoluble fraction from affected brain regions of
GfapR236H/ knock-inmice, which harbor a GFAPmutation homologous to one that causes AxD in humans, and TDP-43 colocalizes with
astrocytic RF pathology in GfapR236H/mice and transgenic mice overexpressing human wild-type GFAP. These findings suggest com-
mon pathogenic mechanisms in ALS, FTLD, and AxD, and this is the first report of TDP-43 involvement in a neurological disorder
primarily affecting astrocytes.
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Introduction
TAR DNA binding protein of 43 kDa (TDP-43) is an essential,
highly conserved DNA/RNA binding protein with diverse func-
tions, including regulation of transcription, splicing, andmiRNA
biogenesis (for review, see Lee et al., 2012). Neurodegenerative
TDP-43 proteinopathies, including the vast majority of cases of
amyotrophic lateral sclerosis (ALS) and frontotemporal lobar de-
generation (FTLD-TDP), are characterized by insoluble TDP-43
pathology (Neumann et al., 2006). Key features of these diseases
are the mislocalization of TDP-43 from the nucleus to the cyto-
plasm and formation of phosphorylated TDP-43-positive intra-
cellular inclusions (Neumann et al., 2006). TDP-43 pathology is
also detected in a variable number of patients with other neuro-
degenerative diseases, including Alzheimer’s, Parkinson’s, and
Huntington’s diseases (Nakashima-Yasuda et al., 2007; Schwab et
al., 2008; Uryu et al., 2008), and TDP-43 pathology is a robust
correlate of aging-related cognitive impairments (Wilson et al.,
2013). Furthermore, TDP-43 was detected in eosinophilic granular
bodies and Rosenthal fibers (RFs) in several cases of low-grade pilo-
cytic astrocytoma (Lee et al., 2008). These findings raise the intrigu-
ing possibility that TDP-43 may play a role in Alexander disease
(AxD), a rare neurodegenerative disease primarily affecting astro-
cytes, in which RF pathology is the hallmark feature with associated
astrogliosis and loss of myelin (Messing et al., 2012).
AxD presents with onset ranging from early infanthood to
mid-life, with signs and symptoms including seizures, encepha-
lopathy, and developmental delay in type I patients (typically
with a younger onset) and bulbar symptoms and ocular/palatal
movement abnormalities with atypical MRI findings in type II
patients (typically with an older onset) (Prust et al., 2011; Mess-
ing et al., 2012). Over 95%of cases are caused bymutations in the
gene encoding glial fibrillary acidic protein (GFAP), which usu-
ally arise de novobut can also be dominantly inherited (Brenner et
al., 2001). More than 106 such disease-linked GFAP mutations
have been identified (Prust et al., 2011). The amino acid most
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commonly mutated is R239, accounting for 20% of all GFAP
mutations (Prust et al., 2011), and knock-in mutation of the
mouse equivalentGfapR236H causes pathological features of AxD,
including increased GFAP levels, formation of eosinophilic RF-
like pathology, and activation of multiple stress pathways (Hage-
mann et al., 2006, 2013). Similarly, overexpression of wild-type
human GFAP inmice causes fatal encephalopathy with AxD-like
pathology (Messing et al., 1998).
Given the broad involvement of TDP-43 in neurodegenera-
tive diseases, and the finding of colocalization of TDP-43 with
RFs in pilocytic astrocytoma, we hypothesized that TDP-43 is
also involved in AxD. Here we show that full-length TDP-43 is
phosphorylated, colocalizes with RFs, and becomes insoluble in
AxD patient CNS tissues. The phosphorylation of TDP-43 corre-
lates with age of disease onset and with the level of GFAP pathol-
ogy, suggesting an active involvement of TDP-43 in disease
pathogenesis. TDP-43 also colocalizes with GFAP in an age-
dependent manner in GfapR236H/ mouse CNS tissues, and
TDP-43 similarly colocalizes with RF-like pathology in wild-type
GFAP overexpressing mice. This is the first report of the involve-
ment of TDP-43 in a degenerative disease primarily affecting
astrocytes, and broadens our understanding of TDP-43 pathol-
ogy in neurodegenerative diseases to include TDP-43 astrocy-
topathies. GfapR236H/ and GFAP overexpressing mice represent
unique models in which to study TDP-43 pathology without di-
rect manipulation of TDP-43 expression levels.
Materials andMethods
Human patient samples. Clinical and genetic details of human CNS sam-
ples are presented in Table 1. Some human CNS tissues were obtained
from the NICHDBrain and Tissue Bank for Developmental Disorders at
theUniversity ofMaryland, Baltimore,MD (supported byNIHContract
#HHSN275200900011C, Ref. No. N01-HD-9-001).
Preparation of human brain lysates. Frontal or temporal white matter
(WM) samples (50–100 mg) were thawed on ice and mechanically ho-
mogenized with 5 volume per weight in high-salt (HS) buffer (50 mM
Tris, 750 mM NaCl, 10 mM NaF, and 5 mM EDTA, pH 7.4). All buffers
were supplemented with 1 mM PMSF and phosphatase and protease
inhibitor cocktails (Sigma). Samples were centrifuged at 100,000 g for
30 min at 4°C and the supernatant taken as the HS-soluble fraction.
Pellets were re-extracted with HS buffer and centrifuged at 100,000 g
for 30 min at 4°C. This supernatant was discarded, and the pellet ex-
tracted by homogenization with 5 volume per original weight in HS
buffer with 1% Triton X-100. Samples were centrifuged at 100,000  g
for 30min at 4°C and the supernatant was taken as theHS-Triton X-100-
soluble fraction. Pellets were extracted by homogenization with 5 vol-
ume per original weight in HS buffer with 1% Triton X-100 and 30%
sucrose and centrifuged at 100,000 g for 30 min at 4°C. This superna-
tant, along with suspended myelin, was discarded, and the pellet was
sonicated with 5 volume per original weight in HS buffer with 1%
Sarkosyl. Samples were incubated at room temperature with agitation
for 30min, and then centrifuged at 100,000 g for 30min at 22°C and
the supernatant taken as the Sarkosyl-soluble fraction. Pellets were
extracted by sonication directly in 1 volume per original weight of SDS
sample buffer (0.05% bromophenol blue, 0.1 M DTT, 10% glycerol, 2%
SDS, and 50 mM Tris, pH 6.8) and then heated at 95°C for 5 min before
immunoblotting.
GFAPmutant and transgenicmice.Knock-inmice heterozygous for the
GfapR236H/ point mutation (Hagemann et al., 2006) and transgenic mice
overexpressing wild-type human genomic GFAP (GFAPTg; Messing et al.,
1998) were generated as previously described andmaintained in the FVB/N
background. Three- and 10-week-oldmalemicewere used for experiments.
All studies were approved by the Animal Care and Use Committee for the
Graduate School at the University ofWisconsin-Madison.
Mouse tissue collection.Mice were killed by CO2 inhalation, and brains
were removed and dissected in ice-cold PBS. Olfactory bulb, hippocam-
pus, and corpus callosumwere immediately frozen in liquid nitrogen and
stored at80°C.
Preparation of mouse brain sections. For frozen sections, mice were
perfused intracardially with room temperature PBS followed by fresh 4%
paraformaldehyde in 0.1 M phosphate buffer, pH 7.4. Brains were post-
fixed overnight at 4°C, cryoprotected in graded concentrations of sucrose
in PBS (5 h at 10%, 20 h at 20%, 48 h at 30%), embedded in
Tissue-Tek O.C.T. compound (Sakura Finetek), frozen in a dry ice/eth-
anol bath, and sectioned at 16 m on a cryostat. For paraffin sections,
mice were killed by CO2 inhalation, and the brains immersion fixed in
10% formalin overnight at room temperature, rinsed in Tris-buffered
saline, pH 7.4 (50mMTris and 150mMNaCl), embedded in paraffin, and
sectioned at 6 m.
Immunofluorescence and immunohistochemistry. For immunofluores-
cence on frozen sections, sections were microwaved in 10 mM citrate
buffer, pH 6.0, for 8 min; blocked in 3% donkey serum (DS) in PBS with
Table 1. Clinical and genetic details of patient samples analyzed by IB and IHC
Case Disease Age at onset Age at death (years) GFAP mutation Sex IHC or IB
AxD 1 Infantile-onset/type I 3 months 1 R239H M IB and IHC (frontal/temporal WM)
AxD 2 Infantile-onset/type I 13 months 6 R239C M IB and IHC (frontal WM)
AxD 3 Infantile-onset/type I 3 months 14 R79C M IB
AxD 4 Juvenile-onset/type II 3.5 years 22 L359V M IB
AxD 5 Adult-onset/type II 37 years 42 D417A F IB and IHC (frontal WM)
AxD 6 Adult-onset/type II 25 years 50 S247P F IB and IHC (frontal WM)
AxD 7 Infantile-onset/type I 1 month 4 months ND M IHC (cortex, cerebellum, brainstem, spinal cord)
AxD 8 Juvenile-onset/type II 1 year 8 R416W M IHC (hippocampus, cortex, medulla)
AxD 9 Adult-onset/type II 14 years 39 Splice site F IHC (frontal, temporal, occipital, hippocampus,
cerebellum, medulla, thoracic spinal cord)
Control 1 Arteriosclerotic cardiovascular disease — 50 — F IB
Control 2 Arteriosclerotic cardiovascular disease — 38 — F IB
Control 3 Cardiac arrhythmia — 14 — M IB
Control 4 Normal — 42 — M IB
Control 5 Normal (metastatic adenocarcinoma) — 51 — F IB and IHC
Control 6 Normal (liver failure) — 46 — F IB
AD 1 Alzheimer’s — 51 — M IB
AD 2 Alzheimer’s/Down’s — 47 — F IB
AD 3 Alzheimer’s — 47 — F IB
FTLD 1 FTLD-C9 35 years 41 — M IB
FTLD 2 FTLD-TDP — 65 — M IHC
AD, Alzheimer’s disease; IB, immunoblotting; IHC, immunohistochemistry; ND, not determined.
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0.25% Triton X-100; incubated with a mouse anti-GFAP monoclonal
antibody (MAb; 1:1000; clone GA5; Millipore MAB3402) and a rabbit
anti-TDP-43 polyclonal antibody (PAb; 1:100; Protein Tech Group
12892-1-AP) in blocking solution; followed by a donkey anti-mouse
Alexa 488-labeled PAb and a donkey anti-rabbit Alexa 546-labeled PAb
(1:1000; Invitrogen) in 3% DS in PBS. Slides were coverslipped using
ProLongGoldmountingmedia withDAPI (Invitrogen) and imaged on a
Nikon C1 confocal microscope. Images are maximum intensity projec-
tions of 7 m z-stacks (7 1 m z-sections per stack). For immunohis-
tochemistry (IHC) on frozen sections, slides were microwaved in 10 mM
citrate buffer, pH 6.0, for 8min; incubated in 3% hydrogen peroxide and
90% methanol; blocked in 3% normal goat serum with 0.25% Triton
X-100; and incubated with a rabbit anti-TDP-43 PAb (1:5000; Protein
Tech Group 12892-1-AP) in blocking solution, followed by biotinylated
goat anti-rabbit PAb. For IHC on paraffin sections, sections were depar-
affinized in xylenes and rehydrated in descending series of ethanol. En-
dogenous peroxidases were blocked with 5% hydrogen peroxide in
methanol, sections were microwaved in 1% antigen unmasking solution
(Vector Laboratories) at 95°C for 15min, blocked in 2%FBS in 0.1 MTris
buffer, and incubated with a rabbit anti-TDP-43 PAb (1:5000; Protein
Tech Group 12892-1-AP), a rabbit anti-TDP-43 PAb (1:6000; Protein
TechGroup 10782-2-AP), a rabbit anti-TDP-43C terminus-specific PAb
[1:5000; CNDR C1039 (Igaz et al., 2008)], a rat anti-phospho-S409/410-
TDP-43 MAb [1:200; clone 1D3, CNDR (Neumann et al., 2009)], a rab-
bit anti-phospho-S403/404 PAb (1:5000; Cosmo Bio TIP-PTD-P05), a
mouse anti-ubiquitinMAb (1:10,000; cloneUbi-1;MilliporeMAB1510),
a rabbit anti-TDP-43 N terminus-specific PAb [1:5000, CNDR N1065
(Igaz et al., 2008)], a rabbit anti-GFAPPAb (1:5000;Dako z0334), or a rat
anti-GFAP MAb [1:5000; clone 2.2B10, CNDR (Lee et al., 1984)] in
blocking solution at 4°C for 16–18 h. Labeling was detected using the
Vectastain ABC kit followed by incubation with 0.05% 3,3-diaminobenzidine
tetrahydrochloride hydrate (Sigma D5637) with 0.003% hydrogen per-
oxide in 0.1 M phosphate buffer, pH 7.4, and sections were counter-
stained with hematoxylin. Slides were coverslipped with VectaMount
AQ aqueous mounting medium (Vector Laboratories) or Cytoseal 60
toluene mounting medium (Thermo Scientific). Images were acquired
using a Nikon Eclipse Ni inverted microscope with DS-Fi2 camera, and
RFs were detected as dense structures visible by hematoxylin or eosin
counterstain.
Preparation of mouse brain lysates.Mouse brain samples were thawed
on ice and sonicated with 5 volume per weight of radioimmunopre-
cipitation (RIPA) buffer (50 mM Tris, 150 mM NaCl, 1% NP-40, 5 mM
EDTA, 0.5% sodium deoxycholate, and 0.1% SDS, pH 8.0) containing 1
mM PMSF and phosphatase and protease inhibitor cocktails (Sigma).
Samples were centrifuged at 100,000  g for 30 min at 4°C and the
supernatant taken as the RIPA-soluble fraction. Pellets were sonicated
with RIPA buffer to ensure removal of all soluble proteins, and centri-
fuged at 100,000 g for 30 min at 4°C. The insoluble pellets were soni-
catedwith 2 volumeper original sampleweight in urea buffer (7Murea,
2 M thiourea, 4% CHAPS, and 30 mM Tris, pH 8.5) and centrifuged at
100,000 g for 30 min at 22°C. The supernatant was taken as the urea-
soluble fraction. Protein concentrations of the RIPA-soluble fraction
were determined using the bicinchoninic acid protein assay (Pierce).
Enzymatic dephosphorylation. Mouse CNS urea-soluble protein frac-
tions were dialyzed using 3.5 kDa MW cutoff dialysis membrane (Spec-
trum Labs) into 50 mM Tris, pH 8.0, with 0.5 mM PMSF for 16 h at 4°C.
Samples were supplemented with reaction buffer and incubated with
-phosphatase (New England BioLabs) for 1 h at 30°C according to the
manufacturer’s protocol, before immunoblotting. Control reactions
were processed in parallel without addition of -phosphatase.
Immunoblotting. Thirty micrograms of RIPA-soluble protein and an
equivalent amount of the corresponding urea-soluble fraction were an-
alyzed by immunoblotting using 10% SDS-PAGE and nitrocellulose
membranes (Bio-Rad). Antibodies for immunoblotting were as follows:
rabbit anti-TDP-43 C terminus PAb (1:10,000; CNDR C1039), rat anti-
phospho-S409/410-TDP-43 MAb (1:100; clone 1D3, CNDR), rabbit
anti-TDP-43 PAb (1:1500; ProteinTechGroup 12892-1-AP), rabbit anti-
GFAP PAb (1:5000; Dako z0334), mouse anti-ubiquitin MAb ([1:1000;
clone 1B4, CNDR (Neumann et al., 2006)], and mouse anti-GAPDH
MAb (1:10,000; clone 6C5; Advanced Immunochemical 2-RGM2). Blots
were incubated with secondary antibodies IRDye 680/800- conjugated
goat anti-mouse or anti-rabbit IgG (Li-Cor) or IRDye 800-conjugated
goat anti-rat IgG (Rockland) PAbs anddeveloped using a Li-CorOdyssey
imaging system. Optical densities of immunobands were quantified us-
ing Li-Cor Image Studio version 2.0 software.
Results
Phosphorylated TDP-43 in RFs of AxD patients
Previously, rare TDP-43 immunoreactivity was detected at the
periphery of RFs in several cases of pilocytic astrocytoma (Lee et
al., 2008). Given that RFs are the hallmark neuropathology in
AxD, we hypothesized that TDP-43 could also be present in the
RF pathology of AxDpatients’ brains and spinal cords.Hematox-
ylin and eosin (H&E) staining was initially performed to confirm
the presence of RF pathology in affected brain and spinal cord
regions of seven confirmed cases of AxD including those with
infantile-onset type I, juvenile-onset type II, and adult-onset type
II disease (Table 1). We analyzed frontal WM from four AxD
cases, and additional regions, including hippocampus, cerebral
cortex, cerebellum, medulla, brainstem, and spinal cord, from
three additional AxD cases. Histological analyses showed that
large, dense eosinophilic RFs, which were immunoreactive at
their periphery for a GFAP antibody, were readily detectable in
affected regions (Fig. 1A,B). IHC using a panel of TDP-43 anti-
bodies revealed peripheral immunoreactivity of RFs for phos-
phorylated (pS409/410) and total TDP-43 in two of the four cases
in which a single frontal WM sample was available (AxD1 and
AxD5; Fig. 1C). Immunostaining of GFAP and normal nuclear
TDP-43 was negative inmultiple runs in the two remaining cases
with only one sample available (AxD2 and AxD6), presumably
due to tissue processing or very long fixation times.
While normal nuclear TDP-43 was detected in adjacent unaf-
fected gray matter (Fig. 1D), up to 50% of RFs in WM of nu-
merous regions, including occipital and temporal WM, medulla,
and thoracic spinal cord, were detected using antibodies specific
for pS409/410 and N-terminal or C-terminal regions of TDP-43
in two of the three cases in which several brain regions were
available for analysis (AxD8 and AxD9; Fig. 1E–G). Tissue from
the remaining case of a 4-month-old boy, AxD 7, did not reveal
TDP-43-positive RFs. Overall, TDP-43 was detected at the pe-
riphery of RFs in four of the seven cases analyzed. Whether the
lack of detection of TDP-43 pathology in the three remaining
cases was due to a lack of TDP-43 pathology or tissue processing/
degradation remains uncertain. In TDP-43-positive cases, IHC
staining was detected by antibodies directed against both
N-terminal and C-terminal regions of TDP-43 (Fig. 1D–F,H),
suggesting incorporation of phosphorylated full-length TDP-43
into the RFs. Notably, the pattern of peripheral RF staining for
TDP-43 was similar to that seen for GFAP, although TDP-43
immunoreactivity was more often detected at the periphery of
smaller thread-like RFs, rather than in larger globular RFs. No
such immunostaining of TDP-43was observed in human control
cases or thosewith a variety of diverse neurodegenerative diseases
(data not shown; Neumann et al., 2006). Furthermore, the pat-
tern of WM TDP-43 pathology in AxD was distinct from the
cytoplasmic inclusions and dystrophic neurites seen in gray mat-
ter of FTLD-TDP patient tissue, and TDP-43-positive inclusions
were not observed in AxD patient neurons (Fig. 1H).
Insoluble TDP-43 is pathologically phosphorylated in AxD
patient WM
The presence of pS409/410 TDP-43 immunoreactivity in RFs
suggested that TDP-43 may be abnormal since phosphorylation
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at these sites was previously detected only in pathological condi-
tions (Neumann et al., 2009). Moreover, the presence of aber-
rantly phosphorylated TDP-43 is usually accompanied by a shift
in solubility and molecular weight. Therefore, pathological
TDP-43 could be rendered insoluble in AxD, similar to the find-
ings of altered solubility in ALS and FTLD patient brain tissue
(Neumann et al., 2006). Todemonstrate the presence of insoluble
pS409/410 TDP-43, human brain samples were sequentially ex-
tracted with buffers of increasing extraction strength and
analyzed for levels of total as well as
phosphorylated TDP-43 in the Sarkosyl-
insoluble but SDS-soluble fractions. Tem-
poral or frontal WM from six AxD
patients was analyzed, along with FTLD-
TDP, Alzheimer’s disease lacking TDP-43
pathology, and non-neurological frontal
WM controls. Although levels of total
TDP-43 were not consistently altered in
AxD patients, a dramatic increase in
pS409/410-TDP-43 was detected in the
three type I AxD cases, representing the
youngest of the six patients analyzed
(AxD1, AxD2, and AxD3; Fig. 2A,B). The
youngest type II AxD case (AxD4) also
had detectable levels of pS409/410-TDP-
43, which were not detected in the two
oldest AxD cases (AxD5 and AxD6) or in
any control or Alzheimer’s disease tissues
(Fig. 2A,B; data not shown). Bands of
45 kDa, corresponding in size to those
in the FTLD-positive control, as well as a
high molecular weight TDP-43 protein
smear, were detected. Furthermore, al-
though 20–25 kDa C-terminal TDP-43
fragments were readily detected in FTLD
control tissue, these TDP-43 fragments
were either absent or present at only very
low levels even in the youngest, most se-
verely affected AxD cases (Fig. 2C, D).
These findings suggest differences in the
post-translational processing of TDP-43
inAxDcomparedwith other TDP-43 pro-
teinopathies, the latter having cleavage of
the protein to generate C-terminal frag-
ments as a prominent feature (Neumann
et al., 2006). Interestingly, the levels of
phosphorylated TDP-43 in AxD patients
correlated with the detection of increased
accumulation of insoluble GFAP and
ubiquitin (Fig. 2E, F), suggesting in-
creased TDP-43 pathology in the most se-
verely affected tissues.
Mislocalized and pathologically
phosphorylated TDP-43 pathology
occurs in mouse models of AxD and
increases with age
We next determined whether TDP-43 pa-
thology also occurs in mouse models of
AxD. GfapR236H/ mice have a point mu-
tation in theGfap gene that is homologous
to the common R239H mutation in hu-
man AxD patients, and these mice exhibit
key features of humanAxD, including widespread RFs, astroglio-
sis, increasedGFAP levels, activation of stress pathways, cognitive
deficits, and susceptibility to seizures (Hagemann et al., 2006,
2013). An antibody directed to theC-terminal portion of TDP-43
(amino acids 260–414, antibody PTG 12892) detected abnor-
mally localized TDP-43 inGfapR236H/mice and the pathological
TDP-43 labeling corresponded to brain regions affected by dis-
ease. In WT control littermates, TDP-43 was mostly confined to
nuclei throughout the brain at both 3 and 10 weeks of age (Fig.
Figure 1. TDP-43 is detected in RF pathology in AxD patients. A, AxD patient tissue shows eosinophilic RFs (arrows) in H&E-
stained affected frontal WM. B, RFs (arrows) are immunoreactive at the periphery for GFAP. IHC for N-terminal (N-t) TDP-43
(antibody N1065) in frontal WM (C) revealed a similar peripheral RF pattern. Normal nuclear TDP-43 was detected in neighboring
temporal cortex (D), compared with RF pathology in temporal WM (E). C-terminal (C-t) TDP-43 (antibody C1039) in medulla (F )
andpS409/410TDP-43 (antibody1D3) in frontalWM(G) reveal peripheral immunoreactivity of RFs (arrows) inAxDpatients,which
is distinct from cytoplasmic inclusions (arrowhead) and dystrophic neurites (asterisk) in frontal cortex of FTLD-TDP patient tissue
(H ). Magnification is consistent between panels. Scale bar: (in H ) A–H, 50m.
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3A,C). In contrast, TDP-43 was found in
the cytoplasmof some cells ofGfapR236H/
mice by 3 weeks of age, especially in re-
gionswhere RFswere detected, such as the
pial surface of piriform cortex (Fig. 3B),
the lacunosum moleculare layer of hip-
pocampus, olfactory bulb, and corpus cal-
losum. Just as GFAP expression levels and
RF-like pathology increase with age, path-
ological TDP-43 labeling similarly in-
creased between 3 and 10 weeks of age
(Fig. 3, compare B,D). More cells exhib-
ited cytoplasmic TDP-43 labeling by 10
weeks, and labeling within individual cells
appeared to extend further away from the
nucleus and cell body into more distal cell
processes (Fig. 3B,D).
In a pattern similar to the increased
GFAP expression in hypertrophic astro-
cytes and RF pathology, pathological
TDP-43 labeling extended into the stra-
tum radiatum, pyramidal layer, stratum
oriens, and external capsule of the hip-
pocampus in 10-week-old mice, detected
with C-terminal TDP-43 antibody (Fig.
3F), pS409/410 (Fig. 3H), and pS403/404
TDP-43 (Fig. 3J). Diffuse TDP-43 immu-
nolabeling inGfapR236H/ cells was visible
throughout the cytoplasm of the cell body
and proximal processes and was more in-
tense in cytoplasm compared with the nu-
cleus, compared with the nuclear TDP-43
immunolabeling inWT littermate control
mice (Fig. 3E,G,I). Punctate TDP-43 im-
munolabelingwas visible in the cytoplasm
of some GfapR236H/ cells (Fig. 3F,H,J in-
sets). The TDP-43 pathology displayed a
similar pattern of expression to GFAP
(Fig. 3L) and ubiquitin (Fig. 3N). More-
over, pS409/410 also detected astrocytic
pathology in olfactory bulb (Fig. 3O) and pial surface of the cor-
tex (Fig. 3P).
Finally, transgenic mice overexpressing human GFAP (GFAPTg
mice) have a more severe phenotype than the GfapR236H/mice, in-
cludingmore RFs and higher levels of GFAP (Messing et al., 1998;
Hagemann et al., 2006). TDP-43 labeling was similarly detected
in hippocampal astrocytic pathology with antibodies against
pS409/410, pS403/404, and total TDP-43 (Fig. 3Q–S). As with
GfapR236H/ mice, GFAPTg mice also showed phosphorylated
TDP-43 pathology in some astrocytic processes, including in the
pial surface of the cortex (Fig. 3T).
Other TDP-43 antibodies, such as C1039 (rabbit polyclonal,
amino acids 394–414) and N1065 (rabbit polyclonal, amino acids
1–260), detectednuclearTDP-43 labeling inbothWTandGfapR236H/
mice, but did not detect significant amounts of cytoplasmic
TDP-43 labeling inGfapR236H/mice despite detecting pathology in
human FTLD-TDP-positive control tissue (data not shown). In
contrast, the N1065 antibody, but not the C1039 antibody, de-
tected a small number of RF-like structures in the GFAPTg mice,
although the pattern of staining was not as extensive as with the
PTG 12892, pS403/404, or pS409/410 antibodies (data not
shown). Notably, both the C1039 and N1065 antibodies did de-
tect RFs in AxD patient tissue (Fig. 1), indicating some differ-
ences in the TDP-43 pathology found inGfapR236H/ andGFAPTg
mice compared with AxD patients. The RF-like pathology found
in thesemousemodels at a relatively young age (3–10weeks)may
not be as “mature” as RFs found in AxD patients, and patholog-
ical TDP-43 may display different abnormal epitopes compared
with human AxD tissues. Additionally, another C-terminal
region-specific TDP-43 antibody, PTG 10782, failed to detect
pathology in both AxD patient tissue and in GfapR236H/ and
GFAPTg mice (data not shown). Conformational changes in the
pathological TDP-43 in RF due to potential interaction with
GFAP may cause selective masking of the epitopes detected by
some of the TDP-43 antibodies used here.
Cytoplasmic TDP-43 colocalizes with GFAP in AxD mice
We next tested whether mislocalization of TDP-43 occurred
specifically in astrocytes using double-label immunofluores-
cence with mouse anti-GFAP and rabbit anti-TDP-43 anti-
bodies in 10-week-old mice. In littermate control WT mice,
TDP-43 was mostly confined to nuclei in olfactory bulb (Fig.
4A) and hippocampus (Fig. 4G). However, in GfapR236H/
mice, TDP-43 was localized to nuclei as well as GFAP-positive
cell bodies and proximal processes in olfactory bulb (Fig.
4D–F, arrows), hippocampus (Fig. 4J–L, arrows), and piri-
Figure 2. Insoluble TDP-43 is phosphorylated in AxD WM tissue samples with low levels of C-terminal TDP-43 fragments.
Immunoblotting of Sarkosyl-insoluble protein from six AxD cases, a control (Con) without a neurological disease, one type-B
FTLD-TDP case, and one Alzheimer control (Alzh) probed for (A) total TDP-43 (antibody C1039) and (B) pS409/410 TDP-43 (anti-
body 1D3) reveals high molecular weight smears and phosphorylated TDP-43 (asterisk) in AxD cases, which correspond to
bands detected in FTLD. Arrow indicates full-length TDP-43. Approximate molecular weight markers (kDa) are shown on
the right. C, D, Increased exposure of blots shown in A and B reveals low levels of25 kDa TDP-43 fragments in four of the
AxD patients. High molecular weight ubiquitinated proteins (E) and GFAP (F ) accumulate in AxD samples with the highest
insoluble TDP-43 burden.
6452 • J. Neurosci., May 7, 2014 • 34(19):6448–6458 Walker, Daniels et al. • TDP-43 in Alexander Disease
form cortex (data not shown). TDP-43 tended to localize to
subcellular regions with a high density of GFAP immunolabel-
ing; however, pathological cytoplasmic TDP-43 immunoreac-
tivity was detected less prominently in more distal astrocytic
processes despite these processes being labeled for GFAP. Ab-
normal TDP-43 accumulation was not detected in neurons
labeled with NeuN (data not shown).
TDP-43 is insoluble and pathologically phosphorylated in
affected AxDmouse tissues
To confirm these IHC data, we conducted immunoblot analyses
to determine the levels of total and phosphorylated TDP-43 in
affected brain regions ofGfapR236H/mice, including corpus cal-
losum, hippocampus, and olfactory bulb. Total TDP-43 levels
were not altered in the RIPA-soluble protein fraction in any re-
Figure3. Mislocalization of TDP-43occurs throughout the brains ofGfapR236H/ andGFAPTgmice and increaseswith age.A–D, TDP-43 immunolabeling (antibodyPTG12892) in coronal sections
of piriform cortex (representative of n 3 mice per genotype). In WT cortex, TDP-43 immunoreactivity is confined to nuclei at 3 weeks (A) and 10 weeks (C). In GfapR236H/ cortex, TDP-43
immunoreactivity is found in the cytoplasm of many cells (arrows) near the pial surface of the brain at 3 weeks (B) and is further increased at 10 weeks (D). E–N, Immunolabeling of mouse
hippocampus at 10 weeks (representative of n  3 mice per genotype). In WT hippocampus, TDP-43 immunolabeling (antibody PTG 12892) is confined to nuclei (E), but in GfapR236H/
hippocampus, TDP-43 is detected in the cytoplasm of astrocytes (F ). Immunolabeling for pS409/410 and pS403/404 TDP-43 shows low level of background nuclear staining in WT (G, I )
but dramatically increased cytoplasmic labeling in GfapR236H/mice (H, J ). Astrogliosis and RF pathology are detected using anti-GFAP antibody in GfapR236H/mice compared with WT
mice (K, L). The cytoplasmic pathology in GfapR236H/mice also contains ubiquitin not detected in WT mice (M, N ). pS409/410 TDP-43 pathology is similarly detected in olfactory bulb
(O) and pial surface of the cortex (P) in GfapR236H/ mice. In GFAPTg mice, astrocytic pathology is also detected by pS409/410, pS403/404 TDP-43, and total TDP-43 antibodies in
hippocampus and cortex (Q–T ). Boxes indicate magnified insets. Scale bars: A–D, 100 m; E–N,100 m; O, P, 25 m; Q–S, 100 m; T, 25 m. Ext, external capsule of the
hippocampus; Or, stratum oriens; Pyr, pyramidal layer.
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gion of the GfapR236H/mice compared with littermate controls,
despite3-fold increased levels of GFAP protein levels (Fig. 5A–
C). In contrast, although total TDP-43 levels in the RIPA-
insoluble fraction were unchanged, a faint upper band was
detected by the C1039 anti-TDP-43 antibody, which was absent
in WT littermate controls. This immunoband was readily dem-
onstrated to be pS409/410 TDP-43 using the anti-pS409/410 an-
tibody (Fig. 5D–F). Moreover, in all affected regions analyzed in
the GfapR236H/ mice, we observed an increase in GFAP in the
RIPA-insoluble fraction, and an increase in high molecular
weight ubiquitinated proteins (Fig. 5D–F).
To investigate the specificity of the phospho-TDP-43 band, we
performed enzymatic dephosphorylation of the RIPA-insoluble
material. Treatment of GfapR236H/mouse hippocampus with
-phosphatase eliminated the pS409/410 TDP-4- immunoreac-
tive species detected by immunoblotting, confirming the speci-
ficity of the antibody in the GfapR236H/mice (Fig. 6).
Discussion
Mislocalization of TDP-43 has previously been detected in a va-
riety of neurodegenerative conditions (for review, see Lagier-
Tourenne et al., 2010; Lee et al., 2012), but it has been rarely
Figure 4. Mislocalized TDP-43 colocalizes with GFAP in GfapR236H/ mice. TDP-43 (red; antibody PTG 12892) and GFAP (green; antibody z0334) immunolabeling in coronal brain
sections from 10-week-old mice (representative of n 3 mice per genotype). Nuclei are labeled with DAPI (blue). In WT mice, TDP-43 is primarily localized to nuclei in olfactory bulb (A)
and the pyramidal layer (Pyr) of the hippocampus (G), with very little colocalization with GFAP (B, C, H, I ). In GfapR236H/mice, TDP-43 is found in cell bodies and proximal processes in
olfactory bulb (D) and hippocampus (J ), and colocalizes with GFAP (arrows in E, F, K, L). Scale bars: A–F, 50 m; G–L, 50 m. Epl, external plexiform layer; Mi, mitral cell layer; Or,
stratum oriens; Rad, stratum radiatum.
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studied in glia or glial degenerative dis-
eases. Here we show that widespread
TDP-43 pathology occurs in astrocytes of
AxD, a primarily astrocytic neurodegen-
erative disease. Human and mouse AxD
CNS samples show that TDP-43 is mis-
localized to the cytoplasm of astrocytes
and becomes increasingly insoluble and
pathologically phosphorylated coincident
with an increase in high molecular weight
ubiquitinated proteins. TDP-43 colocal-
izes with GFAP in RFs, and the amount of
pathological TDP-43 increases with dis-
ease severity in both AxD mouse models
and human AxD patients.
While the cytoplasmic localization,
phosphorylation, and increased insolubil-
ity of TDP-43 in AxD are similar to what
has been reported in other neurodegen-
erative diseases, such as ALS, FTLD-TDP,
Alzheimer’s disease, and Parkinson’s dis-
ease (for review, see Lagier-Tourenne et
al., 2010), TDP-43 pathology in AxD has
several unique characteristics. First, insol-
uble C-terminal fragments of TDP-43
were absent or barely detectable in immu-
noblots of AxD tissue samples, in contrast
to their prevalence in other neurodegen-
erative TDP-43 proteinopathies (Neu-
mann et al., 2006). This supports evidence
from other studies that the presence of
C-terminal fragments of TDP-43 is not
necessary for aberrant cytoplasmic local-
ization, phosphorylation, or insolubility
to occur (for review, see Lee et al., 2012),
and could reflect differences in patholog-
ical TDP-43 processing in neurons compared with astrocytes.
Second, unlike other neurodegenerative disorders characterized
by TDP-43 inclusions, pathological TDP-43 aggregates are lim-
ited exclusively to astrocytes and RFs inGfapR236H/ andGFAPTg
mice as well as in AxD patients. Despite these differences, phos-
phorylated TDP-43 accumulation did occur along with an in-
crease in ubiquitinated proteins, suggesting that normal protein
clearance pathways are disrupted in AxD and that this could be
linked mechanistically to TDP-43 pathology.
The formation of TDP-43 pathology in both GfapR236H/ and
GFAPTg mice occurs in the absence of an increase in TDP-43
protein levels. This is in stark contrast to many previous trans-
genic mouse models of TDP-43 proteinopathy engineered to
overexpress mutant, wild-type, or C-terminal TDP-43 proteins
in which little or no TDP-43 pathology is detected in neurons or
other cell types (for review, see Ling et al., 2013). This suggests
that increasing levels of GFAP above a toxic threshold with sub-
sequent formation of RF pathology induces accumulation of
pathological TDP-43 in amanner that is not recapitulated simply
by increasing TDP-43 expression. It should be noted that the
astrocytic TDP-43 pathology in these mice differs from that seen
in human AxD and other TDP-43 proteinopathies, since pathol-
ogy in the mice was detected poorly by some C- and N-terminal
TDP-43 antibodies despite detecting RFs in AxD patient samples
and inclusions in FTLDusing the conditions described here. This
finding suggests differences in TDP-43 folding in theGfapR236H/
and GFAPTg mice, which renders specific epitopes in TDP-43
Figure5. Levels of RIPA-soluble TDP-43 are unchangedbut phosphorylated TDP-43 is detected in theRIPA-insoluble fraction in
affectedbrain regions ofGfapR236H/mice. Immunoblotting for total TDP-43 (antibody C1039), GFAP, andGAPDHdemonstrate no
change in TDP-43 levels in GfapR236H/ mice compared with littermate controls despite upregulation of GFAP, in RIPA soluble
fractions of corpus callosum (A), hippocampus (B), and olfactory bulb (C). Immunoblotting for total TDP-43 (antibody C1039) and
pS409/410 TDP-43 (clone 1D3) demonstrate the presence of 43 kDa TDP-43 (arrow) as well as a higher TDP-43-immunoreactive
band corresponding to pS409/410 TDP-43 (asterisk) in the RIPA-insoluble fractions of corpus callosum (D), hippocampus (E), and
olfactorybulb (F ) fromGfapR236H/mice,which is not detected in littermate controls.GfapR236H/micealso show increased levels
of GFAP and highmolecular weight ubiquitinated proteins in the RIPA-insoluble fractions. Each blot is representative of duplicate
blots with samples from four 10-week-old GFAPR236H/ mice and four WT littermate controls. Approximate molecular weight
markers (kDa) are shown on the right.
Figure 6. Treatment with -phosphatase eliminates pS409/410 immunoreactivity in hip-
pocampus of GfapR236H/mice. SDS-insoluble fractions from two individual 10-week-old WT
littermate controls and two GfapR236H/mice were dialyzed and treated with-phosphatase
before SDS-PAGE and immunoblotting for (A) total TDP-43 (antibody C1039) and (B) pS409/
410 TDP-43 (antibody 1D3). Approximate molecular weight markers (kDa) are shown on the
right. Asterisk indicates phosphorylated TDP-43, and arrow indicates full-length TDP-43. Re-
sults are representative of two independent experiments analyzing tissues from four individual
mice.
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inaccessible to binding by anti-TDP-43 antibodies. How these
differences in protein folding affect TDP-43 function and accu-
mulation is an interesting area of future study.
TDP-43 pathology has previously been detected in astrocytic
plaques and oligodendroglial inclusions in a small minority of
cases of corticobasal degeneration (Uryu et al., 2008), in astro-
cytes of frontotemporal dementia with familial Lewy body dis-
ease (Lin et al., 2009), in neoplastic cells undergoing mitosis in
low-grade gliomas and astrocytic RFs induced by prolonged gli-
osis in response to chronic brain lesions (Lee et al., 2008), and in
astrocytes of one patient with Cockayne syndrome (Sakurai et al.,
2013). WM TDP-43 pathology has also been detected in FTLD-
TDP, although this is likely predominantly oligodendrocytic
(Neumann et al., 2007). However, this is the first report of a
primarily astrocytic neurodegenerative disease showing TDP-43
pathology. Importantly, accumulation of TDP-43 in astrocytes in
the AxD samples studied here is specifically related to the pres-
ence of RFs, and not reactive gliosis, since pathological TDP-43
distribution was not previously detected in a large series of brain
biopsies of diverse CNS pathologies in which astrogliosis occurs,
including primary and metastatic brain tumors, epilepsy and
stroke (Lee et al., 2008).
The functional significance of astrocytic TDP-43 pathology,
and whether this is involved in neurodegeneration in AxD, re-
mains to be determined.While TDP-43 pathology does not result
in detectable astrocyte death in GfapR236H/ mice, disruption of
TDP-43 function by its mislocalization could cause several
downstream-negative consequences. TDP-43 is involved in RNA
splicing, regulation of transcription, mRNA stabilization, and
miRNA processing and biogenesis, and thousands of RNAs are
bound and potentially regulated by TDP-43 (Freibaum et al.,
2010; for review, see Lagier-Tourenne et al., 2010; Polymenidou
et al., 2011; Sephton et al., 2011; Tollervey et al., 2011; Xiao et al.,
2011; Colombrita et al., 2012). If TDP-43 is sequestered in the
cytoplasm and inRFs, regulation of these RNAs could be affected,
leading to dysfunction of various cellular processes. For example,
TDP-43 has been implicated in neural plasticity (Wang et al.,
2008), cell cycle control (Ayala et al., 2008), mitochondrial func-
tion and trafficking (Shan et al., 2010; Xu et al., 2010), and au-
tophagy (Caccamo et al., 2009; Urushitani et al., 2010; Bose et al.,
2011). Indeed, given that loss of normal nuclear TDP-43 in neu-
rons is postulated as a key mechanism of dysfunction in ALS and
FTLD (Igaz et al., 2011), it is likely that the recruitment of
TDP-43 to astrocytic RFs leads to similar disruption of normal
nuclear TDP-43 functions with detrimental downstream effects
in AxD. Since transactivation of the Gfap promoter is an early
event in pathogenesis in the AxD mouse models (Jany et al.,
2013), and alternative splicing leads to multiple isoforms of both
mouse and human GFAP with varying subcellular distribution
and functional roles (Roelofs et al., 2005; Middeldorp and Hol,
2011; Thomsen et al., 2013), it is possible that alterations in
TDP-43 targets, such as transcription factors or miRNAs, could
lead to increases in GFAP synthesis with subsequent formation of
pathology. Furthermore, postnatal deletion of the key miRNA
endoribonuclease Dicer specifically from astrocytes leads to age-
dependent neurological dysfunction, including ataxia and sei-
zures, resulting in early death (Tao et al., 2011). These findings
indicate that perturbation of miRNA biogenesis in astrocytes, as
may result from TDP-43 mislocalization in AxD, can also lead to
non-cell autonomous neurological disorders.
Another additional mechanism potentially linked to TDP-43
pathology in AxD is the activation of cellular stress pathways.
Numerous cellular stressors, including nutrient deprivation, ox-
idative stress, and endoplasmic reticulum stress, have been
shown to cause cytoplasmic TDP-43 accumulation and associa-
tion with stress granules in a variety of cell culture models (for
review, see Dewey et al., 2012). JNK activation has also been
shown in cell culture to mediate TDP-43 redistribution to the
cytoplasm in response to oxidative stress (Meyerowitz et al.,
2011). Given that in cell culture and Drosophila models of AxD,
oxidative stress-associated JNK pathway activation occurs in a
time-dependent manner (Tang et al., 2006; Wang et al., 2011),
one possibility is that astrocytic stress caused by GFAP accumu-
lation leads to cytoplasmic TDP-43 redistribution, and that ac-
cumulation of TDP-43 within RFs occurs secondarily. The
additional association of TDP-43 with RFs may also reflect its
interaction with the ubiquitin-binding protein p62 (Brady et al.,
2011), which similarly accumulates in RFs (Zatloukal et al.,
2002).
TDP-43 is detected at low levels outside the nucleus and shut-
tles between the nucleus and cytoplasm even under normal con-
ditions (Ayala et al., 2008;Winton et al., 2008; Fallini et al., 2012).
Using electronmicroscopy, GFAP intermediate filaments appear
to be localized near pores in the nuclear envelope, and are asso-
ciated with some mRNAs outside the nucleus (Erickson et al.,
1992). Mutant GFAP or GFAP overexpression may disrupt
nuclear transport of TDP-43, which could further lead to accu-
mulation of TDP-43 in the cytoplasm in AxD. Furthermore, al-
terations in protein degradative pathways in disease also likely
play a role in the accumulation of pathological GFAP and TDP-
43. Although autophagy is increased in AxD and may contribute
to the clearance of GFAP, proteasomal function is impaired, and
so the net effect on GFAP degradation is unclear (Tang et al.,
2006, 2008). However, TDP-43 is degraded via both the
ubiquitin-proteasome (UPS) and autophagy systems (Wang et
al., 2010), and inhibition of the UPS increases phosphorylated
TDP-43 aggregates in cell culture (Winton et al., 2008). These
findings suggest that any perturbation of degradation pathways
in AxD could have concomitant effects on both GFAP and TDP-
43, leading to the accumulation of both pathological proteins.
In conclusion, we extend the scope of neurodegenerative
TDP-43 proteinopathies by demonstrating widespread astrocytic
TDP-43 pathology inAxD,with a particular burdenof phosphor-
ylated TDP-43 in the youngest, most severely affected patients. In
addition, the GfapR236H/ and GFAPTg mouse models also dis-
played considerable astrocytic TDP-43 pathology andmay prove
to be useful tools for studies of the mechanisms underlying
TDP-43 mislocalization, phosphorylation, and accumulation,
with implications for AxD as well as other neurodegenerative
diseases.
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